Growth-stage life science companies rarely fail because of science. They struggle when capital efficiency quietly erodes across the value chain.
I work with biotech and medtech SMEs (15–120 employees) to identify where hidden cost exposure may be distorting burn rate visibility — particularly across:
• CMO and manufacturing contracts
• Regulatory timing assumptions
• Portfolio prioritisation
• Lifecycle misalignment between clinical, CMC and commercial functions
Many leadership teams believe their runway is clear until cross-functional inefficiencies compound and compress optionality. Through a structured 60–90 minute Runway Risk Cost Exposure Review, I help executive teams:
• Stress-test burn rate assumptions
• Surface structural cost leakage
• Identify high-leverage governance adjustments
• Protect valuation narratives
No slide decks. No operational micromanagement. Just disciplined structural analysis. If you are leading a growth-stage life science company and want sharper visibility over cost exposure across the next 12–24 months, feel free to reach out here.
Visit the Life Science Runway Risk & Cost Exposure Audit page for further details on this diagnostic approach.